|
Post by akemp3000 on Nov 6, 2019 19:32:57 GMT -5
I remain highly skeptical that TS for ED ever gets approved. Not because it wouldn’t be awesome to offer an ultra rapid solution but because of the danger of an enibriated user being disappointed and taking a double or triple dose which, with the intended effect of a sudden drop in blood pressure, could be fatal. Al Mann said TS would never be used for ED because of this. He had an I.Q. of about 182. I’m sticking with Al on this until someone can explain why the FDA might approve it with this potential. Maybe the black box warning says, “Do not take when within 100 yards of a woman” 😀
|
|
|
Post by slugworth008 on Nov 6, 2019 19:50:09 GMT -5
I remain highly skeptical that TS for ED ever gets approved. Not because it wouldn’t be awesome to offer an ultra rapid solution but because of the danger of an enibriated user being disappointed and taking a double or triple dose which, with the intended effect of a sudden drop in blood pressure, could be fatal. Al Mann said TS would never be used for ED because of this. He had an I.Q. of about 182. I’m sticking with Al on this until someone can explain why the FDA might approve it with this potential. Maybe the black box warning says, “Do not take when within 100 yards of a woman” 😀 Ah yes, personal responsibility has gone way out the window these days.
|
|
|
Post by slugworth008 on Nov 6, 2019 19:51:25 GMT -5
you guys are incorrect. The uptake of oral penis boosters depend on how much you have eaten prior. 30 mins is empty stomach I think. All I know - Is you better be damn certain that 'the time is right' regardless. Oh......
|
|
|
Post by mnholdem on Nov 6, 2019 19:55:54 GMT -5
So are you going to label whoever is in charge of the tadafill clinical studies "DickHead"? Sorry, but I luv double-entendres and I couldn't resist! On a much more serious note, tadafill is prescribed for high blood pressure in the lungs (pulmonary arterial hypertension). Why are you jumping to a conclusion that this pipeline API is being developed for erectile dysfunction? I seriously doubt that's the plan. The reference to ED is actually right on the slide. See above. Wow. Mann always said that would be way too dangerous because of the drop of blood pressure. Maybe he was thinking of a different API?
|
|
|
Post by cjm18 on Nov 6, 2019 20:14:44 GMT -5
The reference to ED is actually right on the slide. See above. Wow. Mann always said that would be way too dangerous because of the drop of blood pressure. Maybe he was thinking of a different API? Is the risk not the same with pills ? Impatient people might even pop another pill before the first one goes to work.
|
|
|
Post by radgray68 on Nov 6, 2019 21:08:46 GMT -5
Technosphere Tadalafil won't work. Particles get stuck in the throat. Patients complained of really stiff neck. Bahdump bum. 😁
|
|
|
Post by akemp3000 on Nov 6, 2019 21:47:01 GMT -5
Wow. Mann always said that would be way too dangerous because of the drop of blood pressure. Maybe he was thinking of a different API? Is the risk not the same with pills ? Impatient people might even pop another pill before the first one goes to work. Pills work much slower. The result would be fainting...and of course if the erection lasts four hours, the need to tell the doctor...and everyone else they know
|
|
|
Post by lakers on Nov 8, 2019 2:43:15 GMT -5
spencerosborne 05:46 PM $MNKD clarity on an item. I still believe undisclosed molecule is Adcirca (tadalifil). Uthr owns only the PAH indication. As I have written before, mnkd has not licensed ED rights. Is the company serious about making "Puff n Stuff"? Not sure. Announcing intent could be a good way to get Lilly to the table. Even to assist in working to getting UTHR better terms on adcirca fees and royalties. Time will tell. I have previously discussed these dynamics in depth.
|
|
|
Post by sportsrancho on Nov 8, 2019 6:57:02 GMT -5
Good, thanks lakers
|
|
|
Post by myocat on Nov 8, 2019 7:43:53 GMT -5
Afrezza work fast for diabetics. But we can't promote the technology as "Quick in and Fast out". LOL
|
|
|
Post by peppy on Nov 8, 2019 10:03:31 GMT -5
spencerosborne 05:46 PM $MNKD clarity on an item. I still believe undisclosed molecule is Adcirca ( tadalifil). Uthr owns only the PAH indication. As I have written before, mnkd has not licensed ED rights. Is the company serious about making "Puff n Stuff"? Not sure. Announcing intent could be a good way to get Lilly to the table. Even to assist in working to getting UTHR better terms on adcirca fees and royalties. Time will tell. I have previously discussed these dynamics in depth. This; Announcing intent could be a good way to get Lilly to the table. Cialis. (side note; David M. Kendall, came from Lilly)
|
|
|
Post by lakers on Nov 9, 2019 14:36:49 GMT -5
Time tested adage: When things don’t go well, execs tend to fall back to what worked for them in the past.
David Kendal : former Lilly CMO, Cialis -inhaled Tadalafil James Shanon: former GSK CMO, Mnkd Board, Imitrex - inhaled Sumatriptans, Aloxi- inhaled Palonosetron CINV
It’s hard to keep a pill down when you want to vomit.
Global Chemotherapy-induced Nausea and Vomiting (CINV) Market Will Reach $2,659 million by 2022 with Top Key Players GlaxoSmithKline plc, Helsinn Holding S.A., Heron Therapeutics, Inc., Merck & Co., Inc., and Tesaro, Inc
KEY FINDINGS OF THE CINV MARKET STUDY
The Aloxi segment generated highest revenue in the global market in 2015, accounting for over half of the total market. The Netupitant-Palonosetron FDC segment is the fastest growing segment at a CAGR of 10.8%.
The North American market has witnessed a significant growth in the recent years. Presently, it is the largest regional market for CINV drugs and an its market share is anticipated by 2022. Asia-Pacific is the fastest growing market due to increase in number of cancer population, high incidences of gastroenteritis and other diseases that lead to nausea and vomiting. This region boosts up the demand for antiemetic drug due to growth in demand for CINV drugs and is expected to fuel the market growth in this region.
”they are advanced into an animal PK study that will help us get some additional information as we think about dosing in animals and how that's going to correlate to bioavailability of the current available formulations. So, our pipeline slide here has been updated in orange to talk about the two next pipeline slides that went to non-clinical pharmacology, that will help us get better understanding of the absorption through the lungs and really help us understand the dosage form as we continue to progress these in development. We will expect this data pretty much by the end of the year, but full study outcomes in Q1.
UT has not made a decision on the undisclosed compound as they have a right to opt in for a certain period of time, and they are completing a market assessment before making any decisions.”
|
|